KM 391 – Novel Autism Compound KM 277 - Osteo-arthritis and Asthma KM 362 - Demyelination KM 3174 - Early stage developmental compound in the treatment of cancer KM 732 - Reduction of high blood pressure
So there is still a lot of of other drugs in the pipeline but their not moving forward due to focusing on K,B,and P which IMO is a smart move. once money is available either after a partnership or one of the three goes to market I believe they will pick one of these to advance into trials. I think they would go with KM391 which from the small amount of pre-clinical testing that was done it showed promise. This wont happen for another three years IMO but it's great that we have other potential blockbuster drugs that we have just scratched the surface with. Plus if cellceutix is bought out it would help in obtaining a higher price maybe not that much but a little seeing that their pre-clinical status so not actual hard data in humans yet.
News 
Market Data 
Discover 
